Study Reveals Benefits of Combination Therapies for Chronic Migraine

Researchers from the Genomic Medicine Institute and the Center for Neurological Restoration at Cleveland Clinic report new findings suggesting that combination preventive therapy may offer greater relief for patients living with chronic migraine.

Chronic migraine, defined as 15 or more headache days per month for at least three months, with at least eight meeting migraine criteria, remains one of the leading causes of disability worldwide. Despite the availability of modern preventive therapies, many patients continue to experience substantial disease burden and fail to achieve meaningful reductions in monthly migraine days.

Dual Therapy May Outperform Monotherapy

Current preventive strategies for chronic migraine commonly include onabotulinumtoxinA (Botox) and monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway. CGRP plays a central role in migraine pathophysiology, contributing to neurogenic inflammation and pain signaling.

While both therapies have demonstrated efficacy, real-world clinical experience shows that a significant proportion of patients do not achieve the desired 50% reduction in monthly migraine frequency when treated with a single agent.

In a retrospective analysis of 714 Cleveland Clinic patients treated between 2018 and 2021, investigators compared outcomes among those receiving monotherapy (Botox or anti-CGRP monoclonal antibodies) versus those treated with concurrent combination therapy.

Patients receiving dual preventive therapy experienced approximately half as many migraine days per month compared with patients on single-agent regimens, suggesting a potential synergistic effect when targeting multiple mechanisms simultaneously.

Implications for Clinical Practice

These findings reinforce the concept that chronic migraine may require a multifaceted management strategy, particularly for patients who fail to respond adequately to first-line preventive options.

Pairing established treatments such as Botox with anti-CGRP agents may represent a more effective approach for select patients, especially those who remain significantly symptomatic despite optimized monotherapy.

However, logistical and insurance-related barriers often limit access to combination regimens. Coverage policies may restrict patients to a single preventive therapy or delay initiation of newer agents. Investigators note that expanding evidence supporting dual therapy may help inform future policy decisions and clinical guideline updates.

Looking Ahead

As migraine care continues to evolve, research is increasingly focused on precision-guided treatment strategies and improved prediction of therapeutic response.

Combination preventive therapy represents one promising avenue in the effort to reduce migraine-related disability and improve quality of life for patients living with chronic migraine.

Learn more about migraine-focused programming at PAINWeek.

Source: Cleveland Clinic Research, National Library of Medicine